罗沙司他治疗非透析慢性肾脏病贫血的3期随机对照研究(ALPS)
ALPS研究为3期多中心随机双盲安慰剂对照试验,纳入594例3-5期非透析CKD贫血患者,按2:1随机接受口服罗沙司他或安慰剂每周三次治疗52-104周。罗沙司他在欧盟EMA与美国FDA两个主要疗效终点上均优于安慰剂,不良事件发生率两组相当。
要点
- 罗沙司他可显著提高非透析CKD贫血患者的Hb应答率并升高Hb水平
- 罗沙司他可降低LDL-C并延迟首次补救治疗使用时间
- 两组治疗中出现的不良事件发生率相当(87.7% vs 86.7%)
核心结论
- 罗沙司他在Hb应答率和Hb较基线变化两方面均优于安慰剂,安全性特征与安慰剂相当。
研究设计与样本
- 3期多中心随机双盲安慰剂对照研究(NCT01887600),纳入3-5期非透析CKD贫血患者,按2:1随机分组,口服给药每周三次,疗程52-104周。
- 共分析594例患者,罗沙司他组391例,安慰剂组203例。
主要发现
- Hb应答的比值比为34.74(95%CI 20.48-58.93),罗沙司他优于安慰剂。
- Hb较基线变化:罗沙司他减安慰剂为+1.692(95%CI 1.52-1.86),两项主要终点均P<0.001。
- LDL-C较基线变化及首次使用补救药物时间方面罗沙司他均优于安慰剂(均P<0.001)。
- 治疗中出现的不良事件发生率两组相当:罗沙司他87.7%,安慰剂86.7%。
关键数值与推荐
- 欧盟EMA-Hb应答定义:治疗前24周内,基线Hb>8.0 g/dL者Hb≥11.0 g/dL且较基线升高≥1.0 g/dL,或基线Hb≤8.0 g/dL者升高≥2.0 g/dL,且未使用补救治疗。
- 美国FDA终点:基线至第28-52周平均Hb水平的变化,不考虑补救治疗。
临床怎么用
- 对于非透析3-5期CKD贫血患者,可考虑口服罗沙司他纠正贫血并可能改善血脂,需关注其不良事件谱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of chronic kidney disease (CKD) anemia. METHODS: This Phase 3, multicenter, randomized, double-blind, placebo-controlled study examined patients with Stages 3-5 CKD, not on dialysis (NCT01887600). Patients were randomized (2:1) to oral roxadustat or placebo three times weekly for 52-104 weeks. This study examined two primary efficacy endpoints: European Union (European Medicines Agency)-hemoglobin (Hb) response, defined as Hb ≥11.0 g/dL that increased from baseline (BL) by ≥1.0 g/dL in patients with Hb >8.0 g/dL or ≥2.0 g/dL in patients with BL Hb ≤8.0 g/dL, without rescue therapy, during the first 24 weeks of treatment; US Food and Drug Administration-change in Hb from BL to the average Hb level during Weeks 28-52, regardless of rescue therapy. Secondary efficacy endpoints and safety were examined. RESULTS: A total of 594 patients were analyzed (roxadustat: 391; placebo: 203). Superiority of roxadustat versus placebo was demonstrated for both primary efficacy endpoints: Hb response [odds ratio = 34.74, 95% confidence interval (CI) 20.48-58.93] and change in Hb from BL [roxadustat - placebo: +1.692 (95% CI 1.52-1.86); both P < 0.001]. Superiority of roxadustat was demonstrated for low-density lipoprotein cholesterol change from BL, and time to first use of rescue medication (both P < 0.001). The incidences of treatment-emergent adverse events were comparable between groups (roxadustat: 87.7%, placebo: 86.7%). CONCLUSIONS: Roxadustat demonstrated superior efficacy versus placebo in terms of both Hb response rate and change in Hb from BL. The safety profiles of roxadustat and placebo were comparable.
引用
- Shutov E, Sułowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant. 2021. PMID: 33630072. doi:10.1093/ndt/gfab057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。